Psilocybin 6 Times More Helpful Than Nicotine Patches for Smoking, Says New Study

Smoking is an infamously dangerous and hard-to-kick habit, and one that is the leading cause of preventable, premature death globally. Tobacco will claim the lives of up to two-thirds of all long-term tobacco users. If you’re out of luck with gums or patches, a new clinical trial has some potentially exciting news.

Data published in the March 2026 issue of the Journal of the American Medical Association indicates that psilocybin therapy has more than “6 times greater odds” of helping you abstain from smoking than nicotine patches.

Here’s exactly what the study authors did, the mechanisms at play, and what this might mean for those seeking an alternative treatment to conditions like addiction.

Psilocybin vs. Nicotine Patch for Smoking

Published on March 10th, 2026, the trial in question, titled ‘Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial’, by Johnson & colleagues, makes a compelling claim.

“Psilocybin should be investigated further [as a treatment for] tobacco and other substance use disorders,” say the authors, based on their findings. Before we dive into their work, we must acknowledge the context behind their words.

A flat vector style professional illustration in a soft pastel palette soft blues mint greens peaches pale yellows lavenders If there are people they-Apr-24-2026-11-27-13-3976-PM

Psychedelics like psilocybin have been ostracized from the scientific community for decades. Large evidentiary gaps in what we know about psychedelic-assisted therapy (PAT) have developed due to suppression and superstition that, in the 2020s, are finally starting to dissipate.

Researchers are finally lending credence to what psychedelic enthusiasts have known for decades: Compounds like psilocybin have significant potential utility as an alternative aid for various mental health ailments. To that end, Johnson et al. put psilocybin in the ring against nicotine patches - an intervention that, for most people, only works temporarily.

Here’s what they did.

Psilocybin vs. Nicotine Patch: Study Design

82 “psychiatrically healthy” adult smokers
6-month timeframe

Assigned randomly, participants received one dose of 30mg psilocybin or up to 10 weeks of nicotine patch treatment.

Objective: “Compare prolonged smoking abstinence rates” for single-dose psilocybin versus the patch, measured via a 6-month follow-up.

Worth noting: Participants also received cognitive-behavioral therapy (CBT) for both interventions.

Study Findings

Broadly, Johnson & colleagues remarked that psilocybin had significantly greater odds of smoking abstinence after six months: “Most smoking interventions result in modest long-term success,” they said.

“The psilocybin group had more than 6 times greater odds of prolonged abstinence” at a 6-month follow-up. The psilocybin group also smoked half as often each day before abstinence.

Clinical Trial Waiting Area with Soft Pastel Palette-2

The mechanism: The authors believe that psilocybin’s “lack of direct interaction” with brain receptors targeted by traditional smoking interventions is responsible for the benefits seen here.

“[Psilocybin therapy] does not directly alter drug reinforcement…but may act via higher-order psychological systems, such as changes in self-concept and enhanced psychological flexibility.”

What they’re referring to is called neuroplasticity - the brain’s ability to loosen its cognitive holds and carve out new neural connections. This state allows disparate brain regions that don’t usually communicate to establish fresh links, powering the “mind expansion” people feel from psychedelics.

Caveats and Limitations

This study of over 80 individuals presents some reliable, well-constructed data about the potency of psilocybin in managing addiction. However, it is not without some drawbacks.

A small number of adverse events were reported, which “largely consisted” of modest elevations in blood pressure and heart rate among the psilocybin users.
The authors did not “blind” participants. By being aware of the study’s design and intent, “expectancy could have contributed” to the pro-psilocybin findings.
Surprisingly, high retention rates (participants completing the full trial) led the authors to wonder whether participants' motivation to participate in the study may have influenced the outcome. More simply put, did the participants want the results to be what they were, and did they will those results into existence?
Adding CBT to both groups prevented the authors from determining the true amount of impact it had on the results.
Sixty-five percent of participants had a psychedelic experience prior to their participation in the study, which may have influenced outcomes.
The group that received the psilocybin received more contact time with facilitators, which may have influenced outcomes.

It’s also worth acknowledging the practical gap between the interventions. The psilocybin group spent more than double the amount of time in research settings as the nicotine patch users and so received more contact time with facilitators (which may have influenced outcomes) - mostly, the authors admit, because PAT takes 6-8 hours. Nicotine patches can be applied and forgotten about.

Thoughtful Researcher with Balanced Scale in Pastel Palette-1

That convenience and lack of disruption to daily life are huge selling points for anti-smoking tools like the patch. For the time being, psilocybin can’t measure up logistically; it requires you to set aside an entire day in order to follow best practices for set, setting, and integration. But if the evidentiary support continues to grow, the benefits more than offset any practical hurdles.

Psilocybin for Addiction: A New Frontier?

Johnson et al.’s work is compelling, but it represents only a single data point in a larger ecosystem. Most of the existing literature on psilocybin’s medical utility has focused on mental health disorders like major depression or PTSD.

Still, the clinical lens is turning toward psilocybin’s value in managing addiction as well. In 2023, a systematic review and meta-analysis - that’s essentially a study of existing studies, from which the authors draw broader conclusions - acknowledged a “beneficial effect,” but stressed that more research is needed.

Frequently Asked Questions

Can psilocybin help stop smoking?

Psilocybin can potentially help you stop smoking, according to recent studies. More work is needed, but the available data indicate that psilocybin has a role to play in curbing addictive behaviors.

Is psilocybin addictive?

All drugs can be psychologically addictive. That said, there’s no strong evidence suggesting psilocybin is physiologically addictive.

Does psilocybin permanently change your brain?

It may, but research indicates psilocybin causes changes in your brain which last from days to weeks. Integration techniques may extend this period of increased neuroplasticity, helping you to solidify new perspectives.

Can psilocybin break smoking addiction?

Psilocybin may be able to help with smoking and other addictions (including alcoholism), according to emergent research. The exact mechanisms aren’t known, but scientists believe psilocybin circumvents the traditional pathways used by other interventions (which can often fall short) to attack addictive behaviors.

Sources

Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A. Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. JAMA Netw Open. 2026;9(3):e260972. doi:10.1001/jamanetworkopen.2026.0972
Penn A, Yehuda R. Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda. Psychedelic Med (New Rochelle). 2023 Dec 13;1(4):198-209. doi: 10.1089/psymed.2023.0017. PMID: 40046862; PMCID: PMC11658673.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443. PMID: 36322843.
Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014 Jan 8;311(2):193-4. doi: 10.1001/jama.2013.283787. PMID: 24399558.
Grieco SF, Castrén E, Knudsen GM, Kwan AC, Olson DE, Zuo Y, Holmes TC, Xu X. Psychedelics and Neural Plasticity: Therapeutic Implications. J Neurosci. 2022 Nov 9;42(45):8439-8449. doi: 10.1523/JNEUROSCI.1121-22.2022. PMID: 36351821; PMCID: PMC9665925.
Modlin NL, Williamson V, Maggio C, Stubley J, Kirlic N, Cleare A, Rucker J. Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework. Ther Adv Psychopharmacol. 2025 Jun 8;15:20451253251342319. doi: 10.1177/20451253251342319. PMID: 40492108; PMCID: PMC12146596.
van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, Kramers K, Schellekens A, Somers M, Bossong MG, Batalla A. Therapeutic effect of psilocybin in addiction: A systematic review. Front Psychiatry. 2023 Feb 9;14:1134454. doi: 10.3389/fpsyt.2023.1134454. PMID: 36846225; PMCID: PMC9947277.